For laboratory research only
Compare Thymosin beta-4 research suppliers
Listings now default to lowest tracked price per mg. The highlighted price badge is a catalog-price signal only, not a quality, safety, or documentation ranking.
The document count covers six basic checks. “Not found” means we could not confirm it from the public records we reviewed—not that the testing never happened.
Affiliate disclosure: Some links may earn PDD a commission. Affiliate status does not change what we report or how suppliers are ordered.
Elite Research Labs
6 of 6 fields documentedChecked 12 days agoTB-500 (10 mg)
Documented alias catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
$55.24
$5.52 per mg
In stock
Transition Biotech
6 of 6 fields documentedChecked 12 days agoTB-500 (10 mg)
Documented alias catalog match · No active affiliate relationship
Listed price
$61.99
$6.20 per mg
In stock
How Thymosin beta-4 is used in research
Thymosin beta-4 sequesters actin monomers and has been studied in cell motility, corneal and dermal wound models, angiogenesis, and inflammatory responses.
TB-500 is a commercial or experimental label that may refer to a thymosin-beta-4-related fragment or preparation. It should not be assumed to be chemically identical to full-length Tβ4 without sequence documentation.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Cell studies examine actin dynamics, migration, and signaling.
Animal
Dermal, corneal, cardiac, and other injury models have been reported.
Human
Early clinical programs have investigated selected formulations and indications; no FDA-approved drug exists.
What the evidence does not establish
Results depend on the exact molecule, model, and formulation. Full-length Tβ4 evidence cannot automatically support a shortened TB-500 material.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Require the complete sequence; do not accept TB-500 as a sufficient chemical identity.
- Confirm whether the test article is full-length Tβ4 or a fragment.
- Match mass, purity, content, and lot identifiers to the stated molecule.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
Thymosin beta-4 and TB-500 products are not FDA-approved drugs. Thymosin beta-4 and its derivatives are prohibited by WADA.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.